KR20200063147A - Pdl1 표적화 항체 및 이의 사용 방법 - Google Patents

Pdl1 표적화 항체 및 이의 사용 방법 Download PDF

Info

Publication number
KR20200063147A
KR20200063147A KR1020207008775A KR20207008775A KR20200063147A KR 20200063147 A KR20200063147 A KR 20200063147A KR 1020207008775 A KR1020207008775 A KR 1020207008775A KR 20207008775 A KR20207008775 A KR 20207008775A KR 20200063147 A KR20200063147 A KR 20200063147A
Authority
KR
South Korea
Prior art keywords
antibody
seq
pdl1
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207008775A
Other languages
English (en)
Korean (ko)
Inventor
테 군데
마티아스 브록
크리스티안 헤스
알렉산더 시모낭
Original Assignee
누맙 세러퓨틱스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17195781.4A external-priority patent/EP3470429A1/en
Application filed by 누맙 세러퓨틱스 아게 filed Critical 누맙 세러퓨틱스 아게
Priority to KR1020257012651A priority Critical patent/KR20250057935A/ko
Publication of KR20200063147A publication Critical patent/KR20200063147A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Liquid Crystal Substances (AREA)
KR1020207008775A 2017-10-10 2018-10-09 Pdl1 표적화 항체 및 이의 사용 방법 Ceased KR20200063147A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257012651A KR20250057935A (ko) 2017-10-10 2018-10-09 Pdl1 표적화 항체 및 이의 사용 방법

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17195781.4A EP3470429A1 (en) 2017-10-10 2017-10-10 Antibodies targeting pdl1 and methods of use thereof
EP17195781.4 2017-10-10
EP18167094.4 2018-04-12
EP18167094 2018-04-12
EP18180816 2018-06-29
EP18180816.3 2018-06-29
PCT/EP2018/077511 WO2019072869A1 (en) 2017-10-10 2018-10-09 PDL1 TARGETING ANTIBODIES AND METHODS OF USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257012651A Division KR20250057935A (ko) 2017-10-10 2018-10-09 Pdl1 표적화 항체 및 이의 사용 방법

Publications (1)

Publication Number Publication Date
KR20200063147A true KR20200063147A (ko) 2020-06-04

Family

ID=63834022

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207008775A Ceased KR20200063147A (ko) 2017-10-10 2018-10-09 Pdl1 표적화 항체 및 이의 사용 방법
KR1020257012651A Pending KR20250057935A (ko) 2017-10-10 2018-10-09 Pdl1 표적화 항체 및 이의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257012651A Pending KR20250057935A (ko) 2017-10-10 2018-10-09 Pdl1 표적화 항체 및 이의 사용 방법

Country Status (11)

Country Link
US (2) US12077588B2 (cg-RX-API-DMAC10.html)
EP (1) EP3694879A1 (cg-RX-API-DMAC10.html)
JP (3) JP7791650B2 (cg-RX-API-DMAC10.html)
KR (2) KR20200063147A (cg-RX-API-DMAC10.html)
CN (2) CN120248120A (cg-RX-API-DMAC10.html)
AU (2) AU2018348430B2 (cg-RX-API-DMAC10.html)
CA (1) CA3074802A1 (cg-RX-API-DMAC10.html)
IL (2) IL273578B2 (cg-RX-API-DMAC10.html)
MA (1) MA50353A (cg-RX-API-DMAC10.html)
SG (1) SG11202001654TA (cg-RX-API-DMAC10.html)
WO (1) WO2019072869A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110709418B (zh) * 2017-06-05 2023-09-26 努玛治疗有限公司 新型抗hsa抗体
US12202911B2 (en) * 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
SG11202103000WA (en) * 2019-04-26 2021-04-29 I Mab Biopharma Us Ltd Human pd-l1 antibodies
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
PE20260551A1 (es) * 2023-05-19 2026-03-04 Numab Therapeutics AG Dominios variables de anticuerpos y anticuerpos con inmunogenicidad disminuida
IL328540A (en) 2023-12-22 2026-07-01 Numab Therapeutics AG Antibody binding complexes specific for LILRB2

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
ES2367430T3 (es) * 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
CA2911946A1 (en) * 2013-05-10 2014-11-13 Numab Ag Bispecific constructs and their use in the treatment of various diseases
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
KR20250091329A (ko) 2015-06-15 2025-06-20 누맙 세러퓨틱스 아게 이종 이량체 다중 특이적 항체 포맷
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
IL304871A (en) * 2016-01-11 2023-10-01 Inhibrx Inc Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
KR102317479B1 (ko) * 2017-05-05 2021-10-26 노키아 테크놀로지스 오와이 무선 링크 제어 상태 보고

Also Published As

Publication number Publication date
JP7791650B2 (ja) 2025-12-24
JP2023166403A (ja) 2023-11-21
CN120248120A (zh) 2025-07-04
IL273578B1 (en) 2025-11-01
JP2021501569A (ja) 2021-01-21
IL323510A (en) 2025-11-01
US20250066482A1 (en) 2025-02-27
JP7874215B2 (ja) 2026-06-15
CN111225926A (zh) 2020-06-02
US12077588B2 (en) 2024-09-03
CA3074802A1 (en) 2019-04-18
JP7649825B2 (ja) 2025-03-21
EP3694879A1 (en) 2020-08-19
KR20250057935A (ko) 2025-04-29
IL273578A (en) 2020-05-31
AU2025271488A1 (en) 2026-01-08
IL273578B2 (en) 2026-03-01
US20200283528A1 (en) 2020-09-10
WO2019072869A1 (en) 2019-04-18
AU2018348430A1 (en) 2020-03-12
SG11202001654TA (en) 2020-03-30
MA50353A (fr) 2020-08-19
AU2018348430B2 (en) 2025-09-04
JP2025102791A (ja) 2025-07-08
CN111225926B (zh) 2025-03-14

Similar Documents

Publication Publication Date Title
US12202911B2 (en) Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
KR102907326B1 (ko) Cd137을 표적화하는 항체 및 이의 사용 방법
JP7649825B2 (ja) Ｐｄｌ１を標的とする抗体及びそれを用いる方法
EP3470429A1 (en) Antibodies targeting pdl1 and methods of use thereof
EP3636320A1 (en) Antibodies targeting cd137 and methods of use thereof
JP2025020172A (ja) Ｃｄ１３７を標的とする抗体およびその使用方法
KR20260062948A (ko) Ctla4/tigit 결합 단백질 및 이의 의학적 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200326

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211005

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231027

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240730

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20241202

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20250115

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20250115

X601 Decision of rejection after re-examination